Want to see IN:SURAKSHA full AI Analyst Report?
Top Page
Suraksha Diagnostic Ltd.
(SURAKSHA)
Select Model
Select Model
Rating:68Neutral
Price Target:
₹297.00
▼(-1.28% Downside)
Action:Reiterated
Date:05/23/26
The score is driven primarily by solid fundamentals with some profitability/cash-conversion and leverage headwinds, supported by strong technical uptrend signals. Valuation is a meaningful offset due to the high P/E and no dividend yield.
Positive Factors
Multi-year Revenue Growth
Consistent top-line expansion over several years demonstrates durable demand for services and successful market penetration. Sustained revenue growth improves scale economics, supports reinvestment in facilities and technology, and underpins longer-term EBITDA growth if maintained.
Negative Factors
Margin Compression & Volatility
Declining gross and net margins point to structural cost pressure, pricing erosion, or adverse mix changes. Persistent margin volatility undermines earnings predictability, limits free cash generation, and raises execution risk for maintaining investment and return targets over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Multi-year Revenue Growth
Consistent top-line expansion over several years demonstrates durable demand for services and successful market penetration. Sustained revenue growth improves scale economics, supports reinvestment in facilities and technology, and underpins longer-term EBITDA growth if maintained.
Read all positive factors
Suraksha Diagnostic Ltd. (SURAKSHA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹14.17B
Dividend YieldN/A
Average Volume (3M)1.23K
Price to Earnings (P/E)44.2
Beta (1Y)1.12
Revenue Growth23.13%
EPS Growth1.21%
CountryIN
Employees1,300
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)6.13
Shares Outstanding52,080,757
10 Day Avg. Volume1,073
30 Day Avg. Volume1,225
Financial Highlights & Ratios
PEG Ratio32.20
Price to Book (P/B)4.85
Price to Sales (P/S)3.82
P/FCF Ratio70.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)7.7
Revenue Forecast (FY)₹3.35B
Suraksha Diagnostic Ltd. Business Overview & Revenue Model
Company Description
Suraksha Diagnostic Limited operates a chain of diagnostic centers in India. It offers pathology testing services, such as microbiology, serology, molecular biology, histopathology, cytopathology, clinical pathology, and haematology; genomics test...
How the Company Makes Money
null...
Suraksha Diagnostic Ltd. Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
64
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.76B | 3.10B | 2.52B | 2.19B | 1.90B | 2.23B |
| Gross Profit | 1.81B | 1.79B | 2.23B | 1.91B | 762.56M | 862.85M |
| EBITDA | 884.82M | 958.61M | 850.88M | 728.39M | 474.79M | 652.53M |
| Net Income | 319.26M | 321.87M | 318.24M | 236.26M | 65.16M | 208.24M |
Balance Sheet | ||||||
| Total Assets | 3.80B | 4.48B | 3.34B | 3.00B | 2.81B | 2.76B |
| Cash, Cash Equivalents and Short-Term Investments | 435.94M | 263.48M | 226.36M | 515.96M | 522.79M | 412.89M |
| Total Debt | 1.18B | 1.30B | 888.86M | 904.76M | 968.74M | 997.95M |
| Total Liabilities | 1.51B | 2.05B | 1.23B | 1.21B | 1.26B | 1.30B |
| Stockholders Equity | 2.30B | 2.45B | 2.11B | 1.79B | 1.56B | 1.46B |
Cash Flow | ||||||
| Free Cash Flow | 132.32M | 168.14M | 213.35M | 157.90M | 309.29M | 385.74M |
| Operating Cash Flow | 366.93M | 841.59M | 633.59M | 604.84M | 440.96M | 578.23M |
| Investing Cash Flow | -218.05M | -547.84M | -395.84M | -349.96M | -207.95M | -432.81M |
| Financing Cash Flow | -150.27M | -284.07M | -240.48M | -251.30M | -243.28M | -142.85M |
Suraksha Diagnostic Ltd. Technical Analysis
Negative
300.85
Price Trends
284.47
Negative
275.71
Negative
284.73
Negative
Market Momentum
-4.05
Negative
46.14
Neutral
65.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SURAKSHA, the sentiment is Negative. The current price of 300.85 is above the 20-day moving average (MA) of 274.18, above the 50-day MA of 284.47, and above the 200-day MA of 284.73, indicating a bearish trend. The MACD of -4.05 indicates Negative momentum. The RSI at 46.14 is Neutral, neither overbought nor oversold. The STOCH value of 65.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SURAKSHA.
Suraksha Diagnostic Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹276.12B | 54.46 | ― | 0.89% | 12.25% | 3.57% | |
74 Outperform | ₹26.25B | 33.77 | ― | 0.16% | 16.08% | 14.59% | |
73 Outperform | ₹87.50B | 25.89 | ― | 0.68% | 20.61% | 77.73% | |
72 Outperform | ₹111.95B | 58.86 | ― | 0.21% | 23.64% | 29.96% | |
68 Neutral | ₹14.17B | 44.17 | ― | ― | 23.13% | 1.21% | |
55 Neutral | ₹17.64B | 17.47 | ― | 0.38% | 7.75% | 30.21% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:SURAKSHA
Suraksha Diagnostic Ltd.
272.15
-56.30
-17.14%
IN:KRSNAA
Krsnaa Diagnostics Limited
543.80
-154.41
-22.12%
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,647.10
272.23
19.80%
IN:METROPOLIS
Metropolis Healthcare Ltd.
539.95
114.25
26.84%
IN:THYROCARE
Thyrocare Technologies Ltd
549.75
235.77
75.09%
IN:VIMTALABS
Vimta Labs Limited
587.60
139.25
31.06%
Suraksha Diagnostic Ltd. Corporate Events
Suraksha Diagnostic’s Company Secretary and Compliance Officer Resigns
Jun 9, 2026
Suraksha Diagnostic Limited has announced that Ms. Mamta Jain has resigned from her role as Company Secretary, Compliance Officer and Key Managerial Personnel, with her last working day set for July 15, 2026. The board has formally acknowledged he...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.